KRT23 Antibody

What is KRT23 and what is its biological significance?

KRT23 (Keratin 23) is a type I acidic cytokeratin protein that forms part of the intermediate filament cytoskeleton in epithelial cells. It has a molecular weight of approximately 48 kDa and consists of 422 amino acids . KRT23 is highly expressed in several human cancers, particularly colon adenocarcinomas, while being absent in normal colon mucosa . Research has identified it as a PPARA-dependent, MYC-amplified oncogene that plays significant roles in cellular proliferation and DNA damage response pathways .

KRT23 expression is regulated epigenetically, with its promoter being methylated in normal colon mucosa and hypomethylated in most adenocarcinomas . This differential expression pattern suggests potential value as a biomarker in cancer research.

What are the common applications for KRT23 antibodies?

KRT23 antibodies support multiple experimental applications with specific optimal conditions:

These applications allow researchers to investigate KRT23 expression, localization, and function in various experimental contexts, particularly in cancer research .

Which species do commercial KRT23 antibodies typically react with?

Commercial KRT23 antibodies demonstrate varying species reactivity profiles:

When selecting antibodies for non-human studies, verify the specific cross-reactivity claims and validation data provided by manufacturers . The degree of sequence homology between species significantly affects antibody performance.

How can I validate the specificity of a KRT23 antibody for my research?

Comprehensive validation of KRT23 antibodies should include multiple complementary approaches:

• Positive controls: Use cell lines with confirmed KRT23 expression (BxPC-3, HepG2, HeLa cells)

• Knockdown validation: Compare antibody signal between KRT23-depleted and control samples using:

  • siRNA/shRNA-mediated knockdown

  • CRISPR-Cas9 genome editing

• Overexpression systems: Express recombinant KRT23 in low-expressing cell lines

• Western blot verification: Confirm the detected band appears at the expected molecular weight (48 kDa)

• Multiple antibody approach: Use antibodies targeting different epitopes of KRT23 to confirm consistent results

• Tissue validation: Compare expression patterns with published literature (high in colon cancer, low in normal colon)

Thorough validation not only ensures experimental reliability but is increasingly essential for publication in high-impact journals.

What are the optimal antigen retrieval methods for KRT23 detection in FFPE tissues?

Effective antigen retrieval is critical for successful KRT23 detection in formalin-fixed, paraffin-embedded (FFPE) tissues:

*HIER: Heat-induced epitope retrieval

Critical parameters:

• Temperature: Maintain 95-100°C during retrieval

• Duration: 20-30 minutes for most tissues

• Cool-down: Allow gradual cooling to room temperature

• Post-retrieval: Thorough washing before antibody application

As a cytoskeletal protein, KRT23 may be particularly susceptible to fixation-induced epitope masking, making proper retrieval essential for accurate detection .

How does KRT23 expression vary across different tissue types?

KRT23 exhibits distinctive expression patterns with important implications for experimental design:

This differential expression makes KRT23 potentially valuable as a diagnostic biomarker, particularly in gastrointestinal malignancies. When designing experiments, selecting appropriate positive and negative control tissues based on this expression pattern is essential .

How does KRT23 knockdown affect cellular pathways in cancer models?

KRT23 knockdown studies have revealed its involvement in multiple critical cellular pathways:

These findings suggest that KRT23 functions beyond its structural role as a keratin protein, potentially influencing genome stability and cellular survival mechanisms. The interaction with DNA repair pathways is particularly significant, as it suggests potential therapeutic applications for KRT23 targeting in combination with DNA-damaging agents or radiation therapy .

How can contradictory data on KRT23 expression in different studies be reconciled?

Researchers encountering contradictory KRT23 expression data should consider several methodological and biological factors:

Sources of potential contradictions:

• Methodological variables:

  • Antibody diversity: Different epitope targeting and specificities

  • Detection methods: Variations in sensitivity between WB, IHC, qPCR

  • Protocol differences: Fixation, antigen retrieval, signal amplification

• Biological factors:

  • Cancer heterogeneity: Subtypes and stages may have varying expression

  • Tissue-specific regulation: PPARA and MYC influence varies by context

  • Genetic/epigenetic profiles: Underlying variations affect expression

Reconciliation strategies:

• Multi-method validation:

  • Apply multiple detection techniques (IHC, WB, qPCR)

  • Use multiple antibodies targeting different epitopes

  • Include functional validation (knockdown/overexpression)

• Standardized reporting:

  • Document comprehensive methodology

  • Share raw data and validation results

  • Clearly define scoring criteria and thresholds

As noted in research literature, "contradictory data may be interpreted from several aspects," requiring careful contextual analysis and standardized approaches to resolve discrepancies .

How can KRT23 antibodies be used to investigate the role of KRT23 in DNA damage response pathways?

Given KRT23's role in DNA damage response (DDR), antibodies can be deployed in several strategic approaches:

Methodological considerations:

• Damage induction:

  • Ionizing radiation for double-strand breaks

  • Chemotherapeutic agents (cisplatin, doxorubicin)

  • UV radiation or oxidative stressors

• Temporal analysis:

  • Time-course experiments (minutes to days post-damage)

  • Capture both immediate and delayed responses

These approaches have already revealed that KRT23 knockdown decreases expression of key DDR molecules like MRE11A, E2F1, RAD51 and BRCA1, suggesting it may function as a regulator of DNA repair processes .

What considerations are important when designing agonist antibodies targeting KRT23?

While most commercially available KRT23 antibodies are designed for detection rather than functional modulation, the principles of agonist antibody design are relevant for researchers considering therapeutic applications:

Research on other therapeutic antibodies demonstrates that:

• Agonist antibodies often require different design principles than antagonists

• Fc engineering can enhance agonistic activity through clustering

• IgG2 isotypes, particularly the h2B isoform, may promote receptor clustering

• Multi-valent formats often show superior agonistic activity

These principles could inform future development of KRT23-targeting therapeutic antibodies, especially given its role in cancer proliferation and DNA repair.